A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors
Tolcher, A. W., Aylesworth, C., Rizzo, J., Izbicka, E., Campbell, E., Kuhn, J., Weiss, G., Von Hoff, D. D., Rowinsky, E. K.Volume:
11
Journal:
Annals of Oncology
DOI:
10.1023/a:1008398725442
Date:
March, 2000
File:
PDF, 607 KB
2000